NCT05895214 (MESOPANC-01) is a clinical trial of oncological relevance of the mesopancreas in PDAC, sponsored by Heinrich-Heine University, Duesseldorf.

Who is sponsoring NCT05895214?

NCT05895214 is sponsored by Heinrich-Heine University, Duesseldorf.

What drugs are being tested in NCT05895214?

Interventions in NCT05895214: oncological relevance of the mesopancreas.

What condition does NCT05895214 study?

NCT05895214 studies PDAC, Pancreatoduodenectomy, Margin, Resection, Surgery, Local Recurrent Tumor.

Is NCT05895214 still recruiting?

NCT05895214 is currently not yet recruiting. Last updated 8 June 2023.

Last reviewed 2023-06-08 · How we verify

NCT05895214: MESOPANC-01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mesopancreas Study in Pancreatic Cancer

Not yet recruiting Last updated 8 June 2023

What this trial tests

trial testing oncological relevance of the mesopancreas in PDAC in 500 participants. Not yet recruiting.

Timeline

1 June 2023

Primary endpoint
1 January 2025

1 January 2027

Quick facts

Lead sponsor	Heinrich-Heine University, Duesseldorf
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 June 2023
Primary completion	1 January 2025
Estimated completion	1 January 2027
Sites	1 location across Germany

Drugs / interventions tested

oncological relevance of the mesopancreas

Conditions studied

PDAC — all drugs for PDAC →
Pancreatoduodenectomy — all drugs for Pancreatoduodenectomy →
Margin, Resection — all drugs for Margin, Resection →
Surgery — all drugs for Surgery →

Sponsor

Heinrich-Heine University, Duesseldorf

Who can join

18 and older, any sex, with PDAC or Pancreatoduodenectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

After the Introduction of the pathological circumferential resection margin (CRM status by LEEPP Protocol), residual cancer (R1 resection) was most often found in the dorsal and medial resection margins. Yet only the medial resection margin is preoperatively evaluated during staging, while the dorsal resection margin which embeds the mesopancreatic fat and thus resembles the area of the mesopancreas, is not considered during preoperative assessment for resectability. Local recurrence is similarly prevalent as systemic relapse, and revised lower rates of R0CRM- resections through the LEEPP protocol explained the poor local tumor control. The aim of this study is to interdisciplinary approach the circumferential infiltration status of the PDAC concentrating foremost on the mesopancreas of the dorsal resection margin by including anatomic and embryologic derived perspectives.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for PDAC

Currently open trials in the same condition.

NCT07441174 — IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Soli · Phase 1, PHASE2 · recruiting
NCT07252232 — Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) · Phase 3 · recruiting
NCT07145450 — Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With · Phase 1, PHASE2 · recruiting
NCT06515587 — Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer · NA · recruiting
NCT06445062 — Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors · Phase 1, PHASE2 · recruiting

Other Heinrich-Heine University, Duesseldorf trials

Trials by the same sponsor.

NCT04993508 — Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Co · NA · not yet recruiting
NCT07385482 — Chronic and Acute Cardiovascular Diseases in Elderly Intensive Care Patients · not yet recruiting
NCT07455097 — COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) · active not recruiting
NCT07254663 — GEL & MEDication Dysphagia · recruiting
NCT06313944 — German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05895214 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Heinrich-Heine University, Duesseldorf
Last refreshed: 8 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05895214.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing